How T·TIME Cut Enclomiphene Costs in Half for American Men

While enclomiphene is making waves across the U.S., one company is standing out by offering a simpler, more accessible path to treatment. That company is T·TIME, which has managed to price enclomiphene therapy significantly lower than many comparable services. We spoke with them to understand how they pulled it off.

Official program website: ttime.men. On T-Compare you can also open the T·TIME provider listing and the full enclomiphene comparison.

Can either of you give me a one-sentence statement regarding your company?

We’re focused on making low testosterone treatment simpler and more affordable across the United States. Period.

So what exactly are you offering, and why did you decide to get into this space?

More and more men are discovering enclomiphene, a treatment that helps the body produce testosterone naturally while maintaining normal sperm production.

There are other companies offering similar treatments, but in most cases, the process is long and complicated, and enclomiphene is just one of many products they sell.

At T·TIME, we saw an opportunity, both from personal experience and from people around us, to simplify the process and significantly reduce costs. Unlike our competitors, we focus on one thing only: delivering this treatment in the most efficient and accessible way possible.

Where does T·TIME rank on the market in terms of pricing?

It’s among the lowest-priced options currently available for men looking to support their testosterone levels, depending on individual needs.

We offer significantly lower pricing than many competitors providing similar treatments.

At just $2.30 per day, eligible patients can access treatment online without paying for unnecessary overhead or bundled services.

How did you achieve that level of cost-effectiveness compared to other companies?

First, we streamlined the process by removing unnecessary steps while maintaining the clinical review typically associated with testosterone treatments.

There is still a medical screening process in place, but it’s designed to be fast and efficient, not something that delays access. If a patient is ultimately not approved, they receive a full refund.

In addition, we focus on a single product, whereas many competitors offer it alongside a wide range of other services, which often increases overhead and cost.

A growing base of returning customers already receives their treatment delivered directly to their door every three months, a model we’ve found to be both cost-effective and convenient.

Lastly, what do you see for the future of T·TIME?

We plan to stay focused on doing one thing exceptionally well, improving access to this treatment and continuing to streamline the process even further.

This market is growing rapidly, and more people are looking for a reliable and trustworthy way to access enclomiphene. We intend to be there for them.

For current program details, visit ttime.men.